Kalbe Farma Valuation

Is KLBF undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of KLBF when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: KLBF (IDR1565) is trading above our estimate of fair value (IDR581.05)

Significantly Below Fair Value: KLBF is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for KLBF?

Other financial metrics that can be useful for relative valuation.

KLBF key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.3x
Enterprise Value/EBITDA15.9x
PEG Ratio2.3x

Price to Earnings Ratio vs Peers

How does KLBF's PE Ratio compare to its peers?

The above table shows the PE ratio for KLBF vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average12.9x
TSPC Tempo Scan Pacific
8.7xn/aRp8.9t
SOHO Soho Global Health
20xn/aRp8.8t
MERK Merck
11.2xn/aRp1.7t
DVLA Darya-Varia Laboratoria
11.5xn/aRp1.8t
KLBF Kalbe Farma
25.2x10.8%Rp72.4t

Price-To-Earnings vs Peers: KLBF is expensive based on its Price-To-Earnings Ratio (25.2x) compared to the peer average (12.9x).


Price to Earnings Ratio vs Industry

How does KLBF's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.5%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.5%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: KLBF is good value based on its Price-To-Earnings Ratio (25.2x) compared to the Asian Pharmaceuticals industry average (25.2x).


Price to Earnings Ratio vs Fair Ratio

What is KLBF's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

KLBF PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio25.2x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate KLBF's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst KLBF forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentRp1,565.00
Rp1,761.33
+12.5%
17.1%Rp2,800.00Rp1,500.00n/a15
Jun ’25Rp1,490.00
Rp1,761.33
+18.2%
17.1%Rp2,800.00Rp1,500.00n/a15
May ’25Rp1,455.00
Rp1,769.33
+21.6%
16.4%Rp2,800.00Rp1,550.00n/a15
Apr ’25Rp1,465.00
Rp1,788.00
+22.0%
15.8%Rp2,800.00Rp1,570.00n/a15
Mar ’25Rp1,490.00
Rp1,788.00
+20.0%
15.8%Rp2,800.00Rp1,570.00n/a15
Feb ’25Rp1,510.00
Rp1,901.67
+25.9%
17.0%Rp2,800.00Rp1,600.00n/a15
Jan ’25Rp1,610.00
Rp1,999.69
+24.2%
17.3%Rp2,800.00Rp1,600.00n/a16
Dec ’24Rp1,665.00
Rp1,999.69
+20.1%
17.3%Rp2,800.00Rp1,600.00n/a16
Nov ’24Rp1,605.00
Rp2,135.00
+33.0%
13.7%Rp2,800.00Rp1,700.00n/a15
Oct ’24Rp1,755.00
Rp2,218.44
+26.4%
11.1%Rp2,800.00Rp1,700.00n/a16
Sep ’24Rp1,775.00
Rp2,288.24
+28.9%
10.3%Rp2,800.00Rp1,700.00n/a17
Aug ’24Rp1,805.00
Rp2,381.47
+31.9%
6.4%Rp2,800.00Rp2,160.00n/a17
Jul ’24Rp2,050.00
Rp2,381.47
+16.2%
6.4%Rp2,800.00Rp2,160.00n/a17
Jun ’24Rp2,030.00
Rp2,371.94
+16.8%
6.7%Rp2,800.00Rp2,120.00Rp1,490.0018
May ’24Rp2,120.00
Rp2,346.94
+10.7%
7.0%Rp2,800.00Rp2,050.00Rp1,455.0018
Apr ’24Rp2,100.00
Rp2,346.39
+11.7%
7.0%Rp2,800.00Rp2,050.00Rp1,465.0018
Mar ’24Rp2,110.00
Rp2,348.82
+11.3%
7.2%Rp2,800.00Rp2,050.00Rp1,490.0017
Feb ’24Rp2,080.00
Rp2,275.29
+9.4%
6.8%Rp2,500.00Rp1,900.00Rp1,510.0017
Jan ’24Rp2,090.00
Rp2,170.00
+3.8%
9.1%Rp2,490.00Rp1,800.00Rp1,610.0018
Dec ’23Rp2,050.00
Rp2,106.67
+2.8%
10.4%Rp2,400.00Rp1,650.00Rp1,665.0018
Nov ’23Rp1,985.00
Rp2,009.44
+1.2%
8.5%Rp2,400.00Rp1,650.00Rp1,605.0018
Oct ’23Rp1,830.00
Rp1,966.88
+7.5%
7.1%Rp2,250.00Rp1,650.00Rp1,755.0016
Sep ’23Rp1,655.00
Rp1,936.11
+17.0%
6.9%Rp2,200.00Rp1,650.00Rp1,775.0018
Aug ’23Rp1,585.00
Rp1,909.74
+20.5%
7.0%Rp2,100.00Rp1,650.00Rp1,805.0019
Jul ’23Rp1,685.00
Rp1,870.31
+11.0%
8.8%Rp2,100.00Rp1,450.00Rp2,050.0016
Jun ’23Rp1,675.00
Rp1,859.72
+11.0%
8.3%Rp2,100.00Rp1,450.00Rp2,030.0018

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.